Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 3.82% from the stock’s current price. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2029 earnings at $3.35 EPS.

Separately, Piper Sandler restated an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $38.53 on Tuesday. The business has a fifty day moving average price of $38.61 and a two-hundred day moving average price of $24.63. The stock has a market capitalization of $235.11 million, a PE ratio of -19.56 and a beta of 1.18. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, sell-side analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter valued at $45,000. Geode Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $2,861,000. Point72 Asset Management L.P. acquired a new stake in Monopar Therapeutics during the fourth quarter worth approximately $3,694,000. Finally, RA Capital Management L.P. bought a new stake in Monopar Therapeutics in the fourth quarter worth approximately $11,247,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.